Effects of hydroxyurea on extrachromosomal DNA in patients with advanced ovarian carcinomas

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1171-1180

  Raymond, Eric ^a   Faivre, Sandrine ^a   Weiss, Geoffrey ^a   McGill, John ^a   Davidson, Karen ^a   Izbicka, Elzbieta ^a   Kuhn, John G ^a   Allred, Craig ^a   Clark, Gary M ^a   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EXTRACHROMOSOMAL DNA; HYDROXYUREA; PACLITAXEL;

ADULT; AGED; ARTICLE; ASCITES; ASCITES FLUID LEVEL; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOGENETICS; DOUBLE MINUTE CHROMOSOME; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; METAPHASE; OVARY CARCINOMA; PARACENTESIS; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 15; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; HYDROXYUREA; METAPHASE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 0034901952     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Molecular sleuthing: Tracking ovarian cancer progression
2. The importance of circular DNA in mammalian gene amplification
3. Molecular biology of double-minute chromosomes
4. Double-minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines
5. Double minutes are frequently found in ovarian carcinomas
6. Double minutes chromosomes can be produced from precursors derived from chromosomal deletion
7. Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells
8. A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration
9. Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene
10. Amplified dihydrofolate reductase genes in unstable methotrexate-resistant cells are associated with double minute chromosomes
11. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes
12. Autonomously replicating episomes contains mdr1 genes in a multidrug-resistant human cell line
13. Mechanisms of MRP overexpression in four human lung-cancer cell lines and analysis of the MRP amplicon
14. Amplified human MYC oncogenes localized to replicating submicroscopic circular DNA molecules
15. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth
16. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
17. Unstable gene amplification found in breast cancers taken directly from patients
18. Drug-induced loss of unstably amplified genes
19. Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells
20. Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity
21. Use of hydroxyurea to alter drug resistance of human tumor cells
22. Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiform
23. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definition of the treated population
24. Studies of the absorption, distribution, and excretion of hydroxyurea (NSC-32065)
25. Long-term intravenous hydroxyurea infusion in patients with advanced cancer
26. Hydroxyurea (HU) iv 72-hour infusion during intraperitoneal (IP) floxuridine (FUDR) and leucovorin (LV): Pharmacologic/clinical correlates
27. Pharmacokinetics of hydroxyurea in nude mice
28. Determination of hydroxyurea in mammalian tissues and blood
29. A Southwest Oncology Group study of the use of human tumor cloning assay for predicting response in patients with ovarian cancer
30. Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma
31. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis
32. Genetic disparity between morphologically benign cyst contiguous to ovarian carcinomas and solitary cystadenomas
33. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status
34. A randomized crossover trial of parenteral hydroxyurea vs. High-dose Taxol in cisplatin/carboplatin-resistant epithelial ovarian cancer
35. DNA amplification in drug resistant cells and tumors
36. Paclitaxel plus hydroxyurea as second-line therapy for non-small cell lung cancer